MSL DAILY PHARMA NEWS - DARZALEX combination delivers deep and rapid haematologic responses and improved clinical outcomes in newly diagnosed light chain amyloidosis #Darzalex #Haematologic #Amyloidosis “The data demonstrated daratumumab SC in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a significantly higher haematologic complete response rate (CR), 53 percent vs. 18 percent (P<0.0001), compared to CyBorD. AL amyloidosis is a rare and potentially fatal multi-system disorder that occurs when the bone marrow produces abnormal pieces of antibodies called light chains, which clump together to form an amyloid. This amyloid is deposited in tissues and vital organs and interferes with normal organ function. As the disease progresses, many patients experience gradual deterioration to multiple organs, including the heart, kidneys, liver, nervous system and digestive tract. Prognosis is dependent on multiple factors including the pattern and number of organs involved and the treatment regimen. https://www.instagram.com/p/CBjmakxDKda/?igshid=1d4marv3tqkr5
